眼科用医薬品の世界市場レポート 2025年

眼科用医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.7％で574億米ドルに成長します。予測期間の成長は、バイオ医薬品の技術革新、近視の有病率の増加、高齢化人口の拡大、個別化医療へのアプローチ、希少疾患に対する規制当局の支援などに起因すると考えられます。予測期間における主な動向としては、生物製剤と遺伝子治療、ドライアイ治療薬への注目の高まり、緑内障治療の進歩、併用療法の出現、加齢黄斑変性症（AMD）への注目などが挙げられます。

眼科疾患の罹患率の増加は、将来的に眼科薬市場の成長を促進すると予想されます。眼科疾患には、眼とその関連構造に影響を及ぼし、視力障害やその他の眼に関連する問題を引き起こすさまざまな疾患や状態が含まれます。眼科用医薬品は、これらの眼疾患を治療するために特別に設計された医薬品であり、眼疾患の有病率が増加するにつれて、これらの医薬品に対する需要も増加しています。例えば、米国政府機関である疾病対策予防センター（CDC）の報告によると、2022年には40歳以上の米国人の17.2％が少なくとも片目に白内障を患うと予測されており、これは約2,050万人に相当します。このように、眼科疾患の有病率の増加が眼科薬市場の拡大に拍車をかけています。

ヘルスケア支出の急増は、眼科用医薬品市場の成長を後押しすると予想されます。ヘルスケア支出は、眼に関連する疾患の治療薬を含む医療に関連する費用で構成され、医療予算全体の中で眼科用医薬品分野の成長に大きく影響しています。特に、Canadian Institute for Health Informationは、カナダの総医療費が2021年の3,280億米ドルから2022年には3,310億米ドルに0.8%増加すると予測しています。このようなヘルスケア支出の増加は、眼科用医薬品市場の成長軌道を裏付けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界眼科用医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の眼科用医薬品市場：成長率分析
• 世界の眼科用医薬品市場の実績：規模と成長, 2019-2024
• 世界の眼科用医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界眼科用医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の眼科用医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方薬
• 市販薬
• 世界の眼科用医薬品市場：クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗アレルギー
• 抗炎症
• 緑内障予防
• その他のクラス
• 世界の眼科用医薬品市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドライアイ
• 目のアレルギー
• 緑内障
• 眼感染症
• 網膜疾患
• ぶどう膜炎
• その他の病気
• 世界の眼科用医薬品市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体点眼薬
• 固形点眼薬
• 半固形点眼薬
• マルチコンパートメントドラッグデリバリーシステム
• 世界の眼科用医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストア
• オンライン薬局
• 世界の眼科用医薬品市場処方薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 緑内障治療薬
• 抗炎症薬
• 抗生物質
• 抗ウイルス薬
• コルチコステロイド
• その他の処方薬
• 世界の眼科用医薬品市場市販薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 人工涙液
• アレルギー緩和薬
• 赤みの緩和
• 眼のビタミンとサプリメント
• その他の市販薬

第7章 地域別・国別分析

• 世界の眼科用医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の眼科用医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 眼科用医薬品市場：競合情勢
• 眼科用医薬品市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Alcon Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bausch & Lomb Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Santen Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• Nicox S.A.
• Coherus Biosciences Inc.
• Johnson & Johnson
• Otsuka Pharmaceutical Co. Ltd.
• Viatris Inc.
• Mitotech SA
• Akorn Incorporated
• GlaxoSmithKline plc
• Bayer AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 眼科用医薬品市場2029：新たな機会を提供する国
• 眼科用医薬品市場2029：新たな機会を提供するセグメント
• 眼科用医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ophthalmic drugs comprise pharmaceuticals used to treat various eye-related conditions and vision impairments. These medications are often employed in addressing eye infections.

Two primary categories of ophthalmic drugs exist prescription drugs and over-the-counter (OTC) drugs. Prescription ophthalmic drugs necessitate a licensed doctor's or medical practitioner's prescription for acquisition. They encompass classes such as anti-allergy, anti-inflammatory, anti-glaucoma, and others, catering to conditions such as dry eye, eye allergies, glaucoma, eye infections, retinal disorders, uveitis, among others. These drugs are available in diverse dosage forms, including liquid, solid, semisolid, and multicompartment drug delivery systems. Distribution channels for these medications span hospital pharmacies, drugstores, and online pharmacies.

The ophthalmic drugs market research report is one of a series of new reports from The Business Research Company that provides ophthalmic drugs market statistics, including ophthalmic drugs industry global market size, regional shares, competitors with an ophthalmic drugs market share, detailed ophthalmic drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the ophthalmic drugs industry. The ophthalmic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ophthalmic drugs market size has grown strongly in recent years. It will grow from$39.36 billion in 2024 to $42.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing incidence of eye disorders, R&D investments in eye care, changing lifestyles, global increase in diabetes cases, and government initiatives for vision care

The ophthalmic drugs market size is expected to see strong growth in the next few years. It will grow to $57.4 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to biopharmaceutical innovations, increasing prevalence of myopia, expanding aging population, personalized medicine approaches, and regulatory support for rare diseases. Major trends in the forecast period include biologics and gene therapies, increased focus on dry eye therapeutics, advancements in glaucoma treatment, the emergence of combination therapies, and a focus on age-related macular degeneration (AMD).

The rising incidence of ophthalmic disorders is expected to drive growth in the ophthalmic drug market in the future. Ophthalmic disorders encompass a range of diseases and conditions that affect the eye and its associated structures, leading to vision impairment and other eye-related issues. Ophthalmic drugs are pharmaceutical products specifically designed to treat these eye diseases, and as the prevalence of ophthalmic disorders increases, so does the demand for these medications. For instance, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that in 2022, 17.2% of Americans aged 40 and older were projected to have cataracts in at least one eye, which translates to approximately 20.5 million people. Thus, the growing prevalence of ophthalmic disorders is fueling the expansion of the ophthalmic drug market.

The upsurge in healthcare spending is anticipated to bolster the growth of the ophthalmic drugs market. Healthcare expenditure, comprising expenses related to medical care, including medications for eye-related conditions, significantly influences the growth of the ophthalmic drugs sector within the overall healthcare budget. Notably, the Canadian Institute for Health Information forecasted a 0.8% increase in total health spending in Canada from $328 billion in 2021 to $331 billion in 2022. This escalation in healthcare expenditure underscores the growth trajectory within the ophthalmic drugs market.

Product innovation stands as a prominent trend shaping the ophthalmic drug market. Leading companies in this sector concentrate on novel solutions to fortify their market positions. An example is Sun Pharmaceutical Canada Inc.'s launch of CEQUA (cyclosporine ophthalmic solution 0.09% w/v) in January 2022. CEQUA utilizes nanomicellar (NCELL) technology, enhancing drug delivery to ocular tissues by improving cyclosporine's bioavailability and stability, primarily targeting dry eye disease.

Companies focus on developing preservative-free drugs, such as preservative-free latanoprost, offering efficacious treatment options. Thea Pharma introduced Iyuzeh (latanoprost ophthalmic solution) 0.005% in September 2023, the first preservative-free latanoprost approved by the FDA for primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the US. This launch responds to the needs of over 60 million global individuals affected by glaucoma, presenting an effective and preservative-free treatment option within the ophthalmic drugs market.

In November 2022, Alcon Inc., a Switzerland-based leader in eye care, completed the acquisition of Aerie Pharmaceuticals, Inc., a US-based research and development company specializing in ophthalmic disease treatments. The undisclosed deal granted Alcon access to Aerie's existing commercial drug Rhopressa and the developmental drug Rocklatan. This strategic move expands Alcon's pharmaceutical portfolio while leveraging Aerie's research and development capabilities. Alcon aims to harness Aerie's pipeline of ophthalmic drugs, potentially transitioning them into commercially viable treatments. Aerie Pharmaceuticals focuses on innovating drugs for various eye conditions, including dry eye and glaucoma, aligning with Alcon's commitment to advancing eye care solutions.

Major companies operating in the ophthalmic drugs market include AbbVie Inc., Alcon Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Nicox S.A., Coherus Biosciences Inc., Johnson & Johnson, Otsuka Pharmaceutical Co. Ltd., Viatris Inc., Mitotech SA, Akorn Incorporated, GlaxoSmithKline plc, Bayer AG, Senju Pharmaceutical Co. Ltd., Aerie Pharmaceuticals Inc., Kala Pharmaceuticals Inc., Aurobindo Pharma Ltd., Eyevance Pharmaceuticals, Acucela Inc., Dompe Farmaceutici S.p.A., Xbrane Biopharma AB, Laboratoires Thea

North America was the largest region in the ophthalmic drugs market in 2024. The regions covered in the ophthalmic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ophthalmic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The ophthalmic drugs market consists of ophthalmic sales of anti-angiogenic drugs, anti-vascular endothelial growth factor drugs, anti-uveitis drugs, and prostaglandin analogs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ophthalmic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ophthalmic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ophthalmic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ophthalmic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Prescription Drugs; Over-The-Counter Drugs
• 2) By Class: Anti-Allergy; Anti-Inflammatory; Anti-Glaucoma; Other Classes
• 3) By Disease: Dry Eye; Eye Allergy; Glaucoma; Eye Infection; Retinal Disorders; Uveitis; Other Diseases
• 4) By Dosage Form: Liquid Ophthalmic Drug Forms; Solid Ophthalmic Drug Forms; Semisolid Ophthalmic Drug Forms; Multicompartment Drug Delivery Systems
• 5) By Distribution Channel: Hospital Pharmacies; Drug Stores; Online Pharmacies
• Subsegments:
• 1) By Prescription Drugs: Antiglaucoma Agents; Anti-inflammatory Drugs; Antibiotics; Antivirals; Corticosteroids; Other Prescription Drugs
• 2) By Over-The-Counter Drugs: Artificial Tears; Allergy Relief Medications; Redness Relievers; Ocular Vitamins And Supplements; Other OTC Drugs
• Companies Mentioned: AbbVie Inc.; Alcon Inc.; Bausch & Lomb Incorporated; F. Hoffmann-La Roche Ltd.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ophthalmic Drugs Market Characteristics

3. Ophthalmic Drugs Market Trends And Strategies

4. Ophthalmic Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Ophthalmic Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ophthalmic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ophthalmic Drugs Market Growth Rate Analysis
• 5.4. Global Ophthalmic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ophthalmic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ophthalmic Drugs Total Addressable Market (TAM)

6. Ophthalmic Drugs Market Segmentation

• 6.1. Global Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription Drugs
• Over-The-Counter Drugs
• 6.2. Global Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Allergy
• Anti-Inflammatory
• Anti-Glaucoma
• Other Classes
• 6.3. Global Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Eye
• Eye Allergy
• Glaucoma
• Eye Infection
• Retinal Disorders
• Uveitis
• Other Diseases
• 6.4. Global Ophthalmic Drugs Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Ophthalmic Drug Forms
• Solid Ophthalmic Drug Forms
• Semisolid Ophthalmic Drug Forms
• Multicompartment Drug Delivery Systems
• 6.5. Global Ophthalmic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies
• 6.6. Global Ophthalmic Drugs Market, Sub-Segmentation Of Prescription Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiglaucoma Agents
• Anti-inflammatory Drugs
• Antibiotics
• Antivirals
• Corticosteroids
• Other Prescription Drugs
• 6.7. Global Ophthalmic Drugs Market, Sub-Segmentation Of Over-The-Counter Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Artificial Tears
• Allergy Relief Medications
• Redness Relievers
• Ocular Vitamins And Supplements
• Other OTC Drugs

7. Ophthalmic Drugs Market Regional And Country Analysis

• 7.1. Global Ophthalmic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ophthalmic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ophthalmic Drugs Market

• 8.1. Asia-Pacific Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ophthalmic Drugs Market

• 9.1. China Ophthalmic Drugs Market Overview
• 9.2. China Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ophthalmic Drugs Market

• 10.1. India Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ophthalmic Drugs Market

• 11.1. Japan Ophthalmic Drugs Market Overview
• 11.2. Japan Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ophthalmic Drugs Market

• 12.1. Australia Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ophthalmic Drugs Market

• 13.1. Indonesia Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ophthalmic Drugs Market

• 14.1. South Korea Ophthalmic Drugs Market Overview
• 14.2. South Korea Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ophthalmic Drugs Market

• 15.1. Western Europe Ophthalmic Drugs Market Overview
• 15.2. Western Europe Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ophthalmic Drugs Market

• 16.1. UK Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ophthalmic Drugs Market

• 17.1. Germany Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ophthalmic Drugs Market

• 18.1. France Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ophthalmic Drugs Market

• 19.1. Italy Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ophthalmic Drugs Market

• 20.1. Spain Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ophthalmic Drugs Market

• 21.1. Eastern Europe Ophthalmic Drugs Market Overview
• 21.2. Eastern Europe Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ophthalmic Drugs Market

• 22.1. Russia Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ophthalmic Drugs Market

• 23.1. North America Ophthalmic Drugs Market Overview
• 23.2. North America Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ophthalmic Drugs Market

• 24.1. USA Ophthalmic Drugs Market Overview
• 24.2. USA Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ophthalmic Drugs Market

• 25.1. Canada Ophthalmic Drugs Market Overview
• 25.2. Canada Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ophthalmic Drugs Market

• 26.1. South America Ophthalmic Drugs Market Overview
• 26.2. South America Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ophthalmic Drugs Market

• 27.1. Brazil Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ophthalmic Drugs Market

• 28.1. Middle East Ophthalmic Drugs Market Overview
• 28.2. Middle East Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ophthalmic Drugs Market

• 29.1. Africa Ophthalmic Drugs Market Overview
• 29.2. Africa Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ophthalmic Drugs Market Competitive Landscape And Company Profiles

• 30.1. Ophthalmic Drugs Market Competitive Landscape
• 30.2. Ophthalmic Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Alcon Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bausch & Lomb Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Ophthalmic Drugs Market Other Major And Innovative Companies

• 31.1. Pfizer Inc.
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Santen Pharmaceutical Co. Ltd.
• 31.4. Sun Pharmaceutical Industries Limited
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Merck & Co. Inc.
• 31.7. Nicox S.A.
• 31.8. Coherus Biosciences Inc.
• 31.9. Johnson & Johnson
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Viatris Inc.
• 31.12. Mitotech SA
• 31.13. Akorn Incorporated
• 31.14. GlaxoSmithKline plc
• 31.15. Bayer AG

32. Global Ophthalmic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ophthalmic Drugs Market

34. Recent Developments In The Ophthalmic Drugs Market

35. Ophthalmic Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Ophthalmic Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ophthalmic Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ophthalmic Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer